TTK Healthcare final dividend ₹10, AGM July 24, 2026

Key board actions ahead of the 68th AGM

TTK Healthcare has outlined a set of shareholder items ahead of its 68th Annual General Meeting (AGM), including a final dividend recommendation and board-level appointments. The Board has recommended a final dividend of ₹10 (100%) per equity share. The record date for the dividend has been fixed as July 17, 2026.

The company has also placed special resolutions before shareholders covering leadership continuity at the top. These proposals include the reappointment of Mr T T Raghunathan as Executive Chairman and the reappointment of a director who retires by rotation.

The AGM itself is scheduled to be conducted through video conferencing, continuing the format used by many listed companies for shareholder participation and compliance.

Dividend recommendation and record date details

The proposed final dividend is ₹10 per equity share, described as 100%. The company has fixed July 17, 2026 as the record date, which is the cut-off used to determine eligible shareholders for the dividend.

While the article information does not provide the payment date, the disclosure confirms the dividend recommendation and the record date. Dividend proposals typically require shareholder approval at the AGM before being paid.

For investors, the record date is operationally important because eligibility is linked to shareholding status as of that date. Any trading or settlement considerations beyond the record date are not specified in the provided information.

68th AGM schedule and meeting mode

TTK Healthcare’s 68th AGM is scheduled for July 24, 2026. The meeting will be held through video conferencing.

The notice summary provided does not mention the venue, agenda items beyond those highlighted, or voting timelines, but the meeting date and digital mode are clearly stated. The video conferencing format is intended to allow participation without physical attendance.

Special resolution: Executive Chairman reappointment proposal

One of the special resolutions concerns the reappointment of Mr T T Raghunathan as Executive Chairman. The proposed tenure is for five years beginning November 1, 2026.

The remuneration structure cited in the disclosure links his pay to company performance, with remuneration equivalent to 5% of profits. The document does not add further detail on profit definitions or the components of compensation.

The proposal indicates the company is seeking continuity in senior leadership through a fixed term, subject to shareholder approval.

Director retirement by rotation and reappointment item

The board agenda also includes a director retirement by rotation. Mr K Shankaran retires by rotation and has sought reappointment.

Beyond the reappointment request, the text provides background on Mr K Shankaran’s professional profile. He is described as a qualified cost and management accountant and Company Secretary, and as having served as whole-time secretary of the company from 1990 to 2023.

Management profiles highlighted in the disclosure

The provided material also mentions Mr T T Raghunathan’s background. He is identified as Executive Chairman and a Commerce graduate, with “vast industrial experience” and involvement in the management of various companies of the TTK group.

The text also references another director, Mr TT Mukund, without additional detail in the excerpt. No further board composition changes, committee moves, or new appointments are mentioned in the supplied content.

Business context from earlier chairman remarks on medical devices

Separate from the AGM items, the supplied text includes earlier chairman commentary on TTK Healthcare’s medical devices business and its positioning against imports. The remarks state that India’s medical devices market continues to be dominated by imported devices and implants, while TTK Healthcare manufactures products priced competitively.

The comments also refer to government initiatives such as ‘Make in India’ and ‘Atmanirbhar Bharat Abhiyaan’ as supportive of indigenous manufacturing and export potential in medical devices. In the same context, the performance of the heart valve division is described as having posted “decent growth”, while the ortho division recorded “moderate growth”.

Operational backdrop referenced during the pandemic period

The text also contains operational observations from a period when COVID-19 disrupted elective procedures and consumer demand. It states that businesses like heart valves and ortho were running at around 25%-30% levels because they involve elective surgeries while hospitals were treating COVID-19 patients.

It also notes that the company saw a drastic reduction of around 35% in first-quarter sales against a comparable quarter but delivered a cash profit of ₹0.60 crore through initiatives including efficient management of resources.

These statements are presented as historical context within the supplied speech-style material and are not described as current-period performance metrics.

Historical financial highlights mentioned in the text

The supplied content includes financial data points from different periods, including segment-wise revenue and a separate set of annual financial highlights.

TTK Healthcare is described as operating in four major segments: pharma/animal welfare, consumer products, medical devices, and food business. In one year referenced, it recorded a 3% rise in revenue to ₹646 crore, with pharma at ₹231 crore, consumer products at ₹181 crore, protective devices at ₹100 crore, and medical devices at ₹45 crore. The text also states that about ₹30 crore was infused in the medical devices segment.

Another set of figures cited for FY2017-18 states that revenue from operations grew around 9% from ₹527.81 crore to ₹577.55 crore. Pre-tax profit is stated at ₹30.15 crore (previous year ₹29.18 crore), EPS at ₹12.86 on an expanded capital base (previous year ₹24.13), and cash balance at around ₹80 crore. The narrative adds that performance was impacted during the first quarter around the implementation of GST, followed by recovery in subsequent quarters.

Summary table of key AGM facts

Financial figures cited in the supplied text (historical)

Why these disclosures matter for shareholders

The immediate shareholder-relevant items are the proposed final dividend and the AGM resolutions. The record date of July 17, 2026 provides a clear eligibility cut-off for the dividend, while the AGM date of July 24, 2026 sets the decision point for approvals.

The leadership resolution is notable because it seeks a five-year reappointment for the Executive Chairman starting November 1, 2026 and links remuneration to profits at a rate of 5% as stated. The director rotation and reappointment agenda item indicates continuity on the board, subject to shareholder voting.

Closing note

TTK Healthcare’s upcoming 68th AGM on July 24, 2026 will place the ₹10 final dividend recommendation and key board reappointment resolutions before shareholders. The next concrete milestone in the timeline is the dividend record date on July 17, 2026, followed by the AGM vote conducted through video conferencing.